PR Newswire Europe - Long-Term Benefits of Rimonabant Confirmed in Two-Year Study.
NEW ORLEANS, November 9 /PRNewswire/ —
- Results From Rio-North America Trial Show That First Year Improvements in Cardiovascular Risk Factors Maintained in the Second Year of Treatment
Most Popular
When T Make Job Transfers: Good Reasons For Quitting Your Job
Awaken Your Audience: How To Seize Attention In Public Speaking
Time Management Tip: You Have To Track The Hand-offs
Strategic Management Tasks For The Small Business Owner
Market-based government through innovation: How public sector leaders are improving collaboration and focusing on citizens
The results of a two-year Phase III study in 3040 patients with rimonabant (Acomplia(TM)), the first in a new class of therapeutic agents called selective CB1 Blockers, demonstrate that the benefits achieved with rimonabant 20mg at the end of the first year of the study were sustained in the second year of therapy with a good safety and tolerability profile vs. placebo. The two year results of …
Read the rest of this article with a Free Trial at HighBeam Research.
